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Abstract
Testicular cancer is a rare cause of morbidity and mortality in the US. Marked disparities in the 
development of this cancer exist, with testicular cancer being more common in Caucasian men and 
men of higher socioeconomic status. The incidence of testicular cancer is increasing worldwide, 
and the reasons for this have not been well documented. It has been proposed that this increase 
may be due to highly prevalent environmental factors, or from exposure to polychlorinated 
biphenyls, polyvinyl chloride, cigarette smoking, and tetrahydrocannabinol (THC). For our 
analysis, data were obtained from the Oklahoma Central Cancer Registry and the Surveillance, 
Epidemiology and End Results program. Age-adjusted incidence rates and five-year relative 
survival were calculated for Oklahoma and for the US. Overall, incidence was lower in Oklahoma 
than the US, but no differences were observed between the US and Oklahoma regarding survival 
by year of diagnosis, race, age, and stage.
BACKGROUND
Malignant tumors of the testis are rare, with testicular cancer being the 25th most common 
cause of cancer in the US and comprising 0.5% of all new cancer cases.1 Testicular cancer is 
a disease of young men compared to many other cancers, with a median age at diagnosis of 
33.1 A male in the US has a 0.4% chance of being diagnosed with testicular cancer in his 
lifetime.1 In 2012, it was estimated that there were 233,602 men living with testicular cancer 
in the US1 Of the 8,430 new cases of testicular cancer expected in 2015, only 380 deaths are 
expected.1 Testicular cancer has a five-year relative survival rate of 95.3%. However, the 
highest percent of deaths occurs among men aged 20-34, and the median age at death is 41.1
The testes function as part of the male reproductive system, participating in spermatogenesis 
and in the production of androgens, primarily testosterone.2 The primary cell types in the 
testis are the seminiferous tubules, where germ cells participate in spermatogenesis, and the 
interstitial, or Leydig, cells which produce testosterone. Of all primary tumors of the testis, 
90-95% are germ cell tumors. Germ cell tumors are either seminomas or nonseminomas. 
Seminomas tend to be slow-growing tumors that are typically confined to the testes and are 
typically identified in men between 20 and 30 years of age. The nonseminomatous germ cell 
tumors are choriocarcinomas, yolk sac tumors, and teratomas, which tend to grow more 
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quickly and be more aggressive compared to seminomas. The remaining 5-10% of testicular 
tumors are nongerminal neoplasms, or stromal tumors, and consist of Leydig cell tumors, 
Sertoli cell tumors, and gonadoblastomas.2 Stromal tumors are rare, are typically not 
cancerous, and are usually found in children.3
There is marked variation in the development of testicular cancer among different countries, 
races, and socioeconomic classes. In the US, the 2012 incidence rate for testicular cancer 
was 6.7 per 100,000 white men, 1.5 per 100,000 black men, and 4.9 per 100,000 for 
Hispanic men.1 Notable differences in the incidence of testicular cancer have also been 
observed in Europe, both between and within countries. For example, there was a stark 
difference in incidence between neighboring countries Finland (2.5/100,000) and Denmark 
(9.2/100,000), as well as large differences between regions of the same country, with rates 
ranging from 2.8 to 7.9 in different parts of France.4 Many studies have shown that high 
socioeconomic status is associated with a higher risk of testicular cancer.5,6,7
Furthermore, the incidence of testicular cancer is increasing worldwide.4,8 The US has seen 
a significant Annual Percent Change (APC) in the rates of testicular cancer between 
1973-2007.9 From 1973-1977 the incidence rate for Caucasian men was 4.0 per 100,000, 
which increased to 6.4 between 2003-2007, for an APC of +1.4%. The US incidence rate for 
black men was 0.8 per 100,000 men between 1973-1977, which increased to 1.1 per 100,000 
men in 2003-2007, for an APC of +1.9%.9 According to the SEER statistics, the age-
adjusted incidence rate for US men (all races) was 5.6 per 100,000 men between 
2010-2012.1 The death rate from testicular cancer for the same period was 0.3 per 100,000 
men.1
The reason for this increased incidence in testicular cancer is unclear. Improved diagnostic 
techniques and known risk factors, such as cryptorchidism, HIV infection, and fetal estrogen 
exposure are unlikely to explain this trend. Some have suggested that this increase in 
incidence may be due to the presence of highly prevalent environmental factors, which may 
act as endocrine disrupters.10 These distort the normal hormonal activity of the testis and 
altering cellular development.8 The organochlorine p,p’-DDE is a pesticide that was 
commonly used until it was banned in the 1980’s. P,p’-DDE is an androgen receptor 
antagonist, and in a study by Guo et al. (2005), exposure to pesticides was linked to a higher 
incidence of testicular cancer.10 A case-control study by McGlynn et al (2008) also 
associated higher plasma levels of both p,p’-DDE and chlordane with the development of 
testicular germ cell tumor.11 Other substances that have been proposed to be associated with 
an increased risk of testicular cancer are the polychlorinated biphenyls,12 polyvinyl 
chloride,13 and cigarette smoking.14
Of all of the substances postulated to be associated with the development of testicular 
cancer, the one which has been most clearly demonstrated is tetrahydrocannabinol (THC).14 
Several studies have demonstrated an association between having ever smoked marijuana,15 
early (<18 years of age), daily, frequent (>1 time per day) and long-term use of marijuana.16 
The mechanism for this increased risk has not yet been well-described, but cannabinoid 
receptors are found in the hypothalamic-pituitary-gonadal axis, and are found on both 
Leydig and germ cells in the testicle.17 This is an interesting problem facing epidemiologists 
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and urologists today, and certainly more research into the causes and prevention of this 
disease are necessary.
Although variation in the development of testicular cancer has been described in the US and 
worldwide, the descriptive epidemiology of testicular cancer has not been described in 
Oklahoma. The aim of this analysis was to provide a description of the incidence and 
survival of testicular cancer, in the US and Oklahoma.
METHODS
We obtained data on testicular cancer incidence from the Oklahoma Central Cancer Registry 
(OCCR), which included all cases of cancer diagnosed in Oklahoma residents from 
1997-2012. The OCCR is a participant in the National Program of Cancer Registries and 
follows all guidelines of the North American Association of Central Cancer Registries. Data 
for the US were obtained from the Surveillance, Epidemiology, and End Results (SEER) 
program during the same time period, which was designed to be representative of the US 
population.18 We restricted the cases and population to males for calculation of incidence 
rates. We used SEER site recodes to restrict our analysis to men with testicular cancer, 
which included International Classification of Diseases of Oncology, Third Edition/World 
Health Organization (ICDO-3/WHO) 2008 site codes of C620-C629, excluding histology 
codes of 9050-9055, 9140, 9590-9992 (lymphomas, Kaposi sarcoma, and mesothelioma).19 
We obtained the variables of race, ethnicity, year of diagnosis, and age from the OCCR and 
SEER registries for Oklahoma and the US, respectively. We classified race/ethnicity as white 
non-Hispanic (NH), African American NH, American Indian/Alaska Native NH, Asian/
Pacific Islander NH, and Hispanic. For Oklahoma, the OCCR data were linked with Indian 
Health Service records to better classify American Indians/Alaska Natives. We used the 
Derived SEER Summary Stage 2000 variable to classify stage as localized, regional, and 
distant stage in Oklahoma from 1998-2012 and Summary Stage 2000 for stage using SEER 
data. In our analysis of stage at diagnosis, we excluded those reported by a death certificate 
only or on autopsy.
To calculate age-adjusted incidence rates (AAIR), we used the 2000 Standard Population. 
We calculated AAIR by year of diagnosis, grouped into 1997-2001, 2002-2006, and 
2007-2012 for stability purposes. We also calculated AAIR by race/ethnicity using the 
categories specified above. Additionally, we calculated age-specific incidence rates, 
classifying those 0-14 years of age at diagnosis in one group, separating those who were 
15-64 at diagnosis into five-year age groups, and combining those 65 years and older at 
diagnosis in to a single group.
To determine five-year relative survival in Oklahoma, we first calculated observed survival, 
then used SEER expected survival life tables20 from 1997-2008 to calculate relative survival 
using the methods developed by Dickman 2004 in SAS v. 9.4.21 In order to have more 
complete follow-up through November 1, 2014, we limited our years of diagnosis to 
1997-2008. We calculated survival by race, age, year of diagnosis (1997-2001 and 
2002-2008), and stage. We classified race as white, African American, and other (American 
Indian/Alaska Native and Asian/Pacific Islander) due to the availability of race 
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classifications in the expected survival life tables. Hispanic ethnicity was not available in the 
expected survival life tables. To compare survival over time, we dichotomized the year of 
diagnosis into 1997-2001 and 2002-2008 for stability and confidentiality reasons. For age-
specific survival, we classified age as 0-14 years, five-year age groups through 59 years of 
age, and 60 and older, again for confidentiality and stability reasons. We used the same 
staging classifications for the survival analysis as defined for the incidence calculations. We 
excluded those cases who were identified by death certificate and autopsy only from the 
analysis.
We used SEER*Stat software to obtain incidence rates and five-year relative survival for 
SEER data. We used SAS v. 9.4 for all analyses of Oklahoma data. This study was approved 
by the Institutional Review Boards of the University of Oklahoma Health Sciences Center 
and the Oklahoma State Department of Health.
RESULTS
Incidence
The AAIR for testicular cancer in Oklahoma was 4.9 per 100,000 among those diagnosed 
between 1997 and 2012, which was lower than the AAIR in the US (5.5 per 100,000) (Table 
1). In Oklahoma, 65.3% (n=842) were diagnosed at local stage, 17.2% (n=222), were 
diagnosed at regional stage, and 11.7% (n=151) were diagnosed at distant stage (5.5%, n=71 
unknown) from 1998-2012. This distribution was similar to that in SEER data during this 
period (Local: 66.7%, n=21,923; Regional: 17.2%, n=5632; Distant: 11.2%, n=3,671; 
Unknown: 4.7%, n=1,547). In the US and Oklahoma, the incidence was highest in white NH 
(US: 7.4 per 100,000; OK: 5.4 per 100,000), followed by American Indians/Alaska Natives 
(AI/AN) NH (US: 5.6 per 100,000; OK: 5.3 per 100,000), and Hispanics (US: 4.3 per 
100,000; OK: 4.1 per 100,000). The AAIRs by race/ethnicity were similar in the US and 
Oklahoma with the exception of white NH, where the AAIR was lower in Oklahoma (5.4 
per 100,000) than in the US (7.4 per 100,000). AAIR were also similar by year of diagnosis, 
however, the AAIR in Oklahoma was lower for those diagnosed from 2007-2012 (5.1 per 
100,000) compared to the US (5.8 per 100,000). In both Oklahoma and the US, incidence 
was highest among those between the ages of 25 and 40 years of age. Oklahoma men 
diagnosed at ages 15-19 years (2.5 v. 3.8 per 100,000), 20-24 years (7.7 v. 9.9 per 100,000), 
and 25-29 years (11.4 v. 13.5 per 100,000) had a lower age-specific incidence rate than the 
US, but no other age-specific differences were present.
Survival
Overall, the five-year relative survival from testicular cancer was 95.3% in the US and 
93.6% in Oklahoma (Table 2). Based on the overlapping 95% CI, we observed no 
differences between the US and Oklahoma regarding survival by year of diagnosis, race, 
age, and stage. There was no difference in the US for survival by time period. Regarding 
race, those with unknown race had the highest relative survival in the US (99.1%), followed 
by white (95.6%), other (91.4%), and African Americans (88.9%). In Oklahoma, those of 
unknown race (100.0%) and African Americans (98.5%) had the highest relative survival, 
although the confidence intervals overlapped the estimates for other racial groups. In both 
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the US and Oklahoma, survival was lowest among those 60 years and older (US: 84.4%, 
OK: 80.5%). Survival was above 70% regardless of stage, but highest among those 
diagnosed at local stage (US: 97.4%, OK: 97.4%).
DISCUSSION
Testicular cancer is rare in Oklahoma and the US and survival is above 90%. Age-adjusted 
incidence rates of testicular cancer were higher in the US than in Oklahoma, particularly 
among white NHs, men 15-19 years of age, and men 20-24 years of age. However, survival 
did not differ by year of diagnosis, race, age at diagnosis, and stage in Oklahoma compared 
to the US.
Caucasian men get testicular cancer at a rate five to six times higher than African American 
men.9 The reasons for this are largely unknown, although recent research has demonstrated 
an association between a single nucleotide polymorphism affecting a p53 binding site on the 
KITLG gene and the development of testicular cancer.22 This single-nucleotide 
polymorphism (SNP) is observed at a much higher rate in European Caucasians than in 
those of African descent. This SNP may have been naturally selected for in European 
Caucasians, as it also plays a role in protection from UV damage in light-skinned 
individuals.22
While Caucasian men are more likely to develop testicular cancer, studies have 
demonstrated that non-Caucasian men tend to have worse outcomes.23,24 A review of 215 
patients with testicular cancer found no differences in tumor type nor stage at presentation 
between white and non-white men. This same analysis showed that there was no statistically 
significant difference in survival between Hispanic and white patients, but that African 
American patients had a 17% decrease in survival compared to white patients.24 
Furthermore, another study reported that African American race and low SES appeared to 
predispose men to more advanced disease stages, and that men of African American race 
and men with low SES had higher overall mortality and cancer-specific mortality than 
Caucasian patients.23 More recent research has shown that testicular cancer-specific survival 
between races is converging over time, and suggests that diagnostic and treatment 
discrepancies between racial groups may be improving for non-Caucasian patients.25
An advantage of this study was the ability to obtain data from population-based registries in 
Oklahoma and the US to evaluate a rare cancer. Both registries are high quality and have 
data available over a long period of time, particularly SEER. Furthermore, we were able to 
use the same data sources to compare both incidence and survival. One limitation to our 
survival analysis was the inability to calculate relative survival for AI/AN, Asian/Pacific 
Islanders, or the Hispanic population due to limitations in the expected survival tables. This 
prevented us from understanding how survival differs by all race and ethnic groups, 
particularly AI/ANs, which account for 9.0% of the population in Oklahoma compared to 
1.2% in the US.26 Furthermore, while the OCCR conducts follow-up on all cases of cancer 
included in the registry, some cases may be lost to follow-up due to migration out of the US. 
Because the OCCR links with the Oklahoma Mortality Data, the Social Security Death 
Index, and the National Death Index, vital status is more complete accounting for lag time 
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for death reporting. However, because OCCR does not link with the National Death Index 
each year, the survival may be overinflated. For this study we used the presumed alive 
methodology as it has been shown to be comparable to SEER follow-up methods.27, 28
Testicular cancer is a rare cause of cancer, both in terms of incidence and in cancer deaths. 
Marked disparities exist in the development of testicular cancer, with Caucasian men being 
at the highest risk. There is little that can currently be done in terms of prevention since 
etiology is unknown, and the current guidelines recommend against screening for this 
disease. Fortunately, most cases of testicular cancer are diagnosed at an early stage, and 
prognosis is excellent in terms of five-year relative survival, even in those with late-stage 
disease. Future studies should consider evaluating incidence among multiple states in a 
region to better understand time trends at a smaller geographic level than the entire US.
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Table 1
Testicular cancer incidence rates per 100,000 for Oklahoma and the US by race/ethnicity, 
year of diagnosis, and age
Characteristic SEER Incidence Rate
per 100,000 (95% CI)
Oklahoma Incidence Rate
per 1000,000 (95% CI)
Overall
a 5.5 (5.5, 5.6) 4.9 (4.7, 5.2)
Year of Diagnosis
a
 1997-2001 5.3 (5.1, 5.4) 4.7 (4.2, 5.2)
 2002-2006 5.5 (5.3, 5.6) 5.1 (4.7, 5.6)
 2007-2012 5.8 (5.7, 5.9) 5.1 (4.6, 5.5)
Race/Ethnicity
a
 White non-Hispanic (NH) 7.4 (7.3, 7.5) 5.4 (5.1, 5.7)
 African American NH 1.5 (1.4, 1.6) 1.4 (0.9, 1.9)
 American Indian NH 5.6 (4.8, 6.4) 5.3 (4.4, 6.2)
 Asian/Pacific Islander NH 2.2 (2.0, 2.3) 1.9 (0.1, 3.6)
 Hispanic 4.3 (4.1, 4.4) 4.1 (3.0, 5.1)
Age
 0-14 years 0.3 (0.2, 0.3) 0.2 (0.1, 0.3)
 15-19 years 3.8 (3.5, 4.0) 2.5 (1.9, 3.2)
 20-24 years 9.9 (9.5, 10.3) 7.7 (6.5, 8.8)
 25-29 years 13.5 (13.0, 13.9) 11.4 (9.9, 12.9)
 30-34 years 13.5 (13.1, 14.0) 13.6 (11.9, 15.3)
 35-39 years 11.5 (11.1, 11.9) 10.9 (9.4, 12.3)
 40-44 years 9.2 (8.8, 9.6) 8.4 (7.1, 9.7)
 45-49 years 6.4 (6.1, 6.8) 5.5 (4.5, 6.6)
 50-54 years 4.1 (3.8, 4.4) 4.1 (3.2, 5.0)
 55-59 years 2.5 (2.3, 2.8) 2.1 (1.4, 2.8)
 60-64 years 1.8 (1.5, 2.0) 2.1 (1.3, 2.9)
 65+ 1.1 (1.0, 1.2) 1.1 (0.7, 1.4)
a
Rates age-adjusted to the 2000 US Standard Population
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Table 2
5-year relative survival estimates for testicular cancer for Oklahoma and the US by race/
ethnicity, year of diagnosis, age, and stage
Characteristic SEER 5-Year Relative Survival
(95% CI)
Oklahoma 5-Year Relative Survival
(95% CI)
Overall 95.3 (94.9, 95.6) 93.6 (91.9, 95.3)
Year of Diagnosis
1997-2001 95.4 (94.8, 95.9) 93.1 (90.3, 95.9)
2002-2008 95.2 (94.7, 95.6) 93.9 (91.7, 96.0)
Race
White 95.6 (95.2, 95.9) 93.8 (92.0, 95.6)
African American 88.9 (86.0, 91.3) 98.5 (89.5, 100.0)
Other 91.4 (89.2, 93.1) 90.1 (84.2, 96.0)
Unknown 99.1 (96.6, 99.8) 100.0 (100.0, 100.0)
Age
0-14 years 96.7 (93.1, 98.4) 100.0 (100.0, 100.0)
15-19 years 92.6 (90.7, 94.0) 97.9 (93.0, 100.0)
20-24 years 94.1 (93.1, 95.0) 96.6 (93.2, 100.0)
25-29 years 95.8 (95.0, 96.4) 94.5 (90.8, 98.2)
30-34 years 96.0 (95.3, 96.7) 91.7 (87.7, 95.8)
35-39 years 96.3 (95.5, 96.9) 95.2 (91.5, 98.9)
40-44 years 96.0 (95.1, 96.8) 92.2 (87.1, 97.3)
45-49 years 95.3 (94.0, 96.3) 94.9 (89.1, 100.0)
50-54 years 95.8 (94.0, 97.1) 93.6 (85.1, 100.0)
55-59 years 92.9 (89.5, 95.3) 94.5 (80.7, 100.0)
60+ years 84.4 (79.3, 88.4) 80.5 (63.9, 97.1)
Stagea
Local 99.2 (98.9, 99.4) 97.4 (95.8, 99.0)
Regional 95.7 (94.9, 96.4) 92.2 (87.5, 96.9)
Distant 72.0 (70.1, 73.8) 75.9 (67.2, 84.7)
Unknown 85.9 (81.1, 89.5) 85.7 (75.4, 95.9)
a
Survival by stage is limited to 1998-2008 to be consistent with the SEER Summary Stage 2000 variable.
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